New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Evolva to acquire Abunda Nutrition

Evolva Holding SA plans to acquire its R&D partner Abunda Nutrition, Inc. Evolva and San Francisco-based Abunda have collaborated on the development of Abunda’s next-generation nutritional ingredients since 2009.

Evolva Holding SA (SIX: EVE) announces that it plans to acquire its R&D partner Abunda Nutrition, Inc.

Evolva and San Francisco-based Abunda have collaborated on the development of Abunda’s next-generation nutritional ingredients since 2009. One part of this collaboration, using Evolva’s proprietary technology, succeeded in making the key components of the natural high intensity sweetener Stevia via fermentation in yeast. This process bypasses the complex logistics associated with the traditional cultivation, processing and refining of Stevia plants, and allows pure Stevia sweetness components to be produced.

The value of the global sweetener market is currently estimated at USD 70 billion p.a., with sugar the dominant product. Within this market, Stevia-based sweeteners are the fastest growing segment, with demand driven in part because Stevia extracts have 200-300 times the sweetness of sugar, but also because of increasing consumer demand for health, wellness, and performance products that are low-carbohydrate and low-sugar. By enabling the introduction of new sweetener products with compelling health, taste and other benefits for consumers, pure fermentation-derived Stevia components can potentially take an important part of the overall sweetener market.

In addition to Stevia, Evolva will obtain full ownership of certain additional development-stage compounds with relevance in cardiovascular health and other nutrition sectors. Clinical nutrition trials have been conducted on selected compounds.

Under the terms of the proposed merger, Evolva will acquire 100% of the share capital of Abunda in return for 25 million Evolva shares (12.9% of Evolva’s share capital post transaction, fully diluted). If certain value-creating milestones are achieved in the 19 months after closing, Abunda shareholders are entitled to receive up to an additional 12 million shares and, for three years afterward, a low-teen percentage share of cash returns from the Abunda assets.

Abunda brings sufficient cash for the development of its product portfolio through year-end 2012, and the transaction would not affect Evolva’s cash runway. As a result of internalising a currently external program the transaction would increase Evolva’s expected 2011 cash outflow from operations and investments from CHF 20m to CHF 22m (2010: CHF 18.1m) and result in a modest decrease in 2011 revenues. These would be offset by an increase in cash on Evolva’s balance sheet upon completion of the transaction. There would also be non-cash charges to Evolva’s 2011 income statement reflecting current Abunda option plans.

The terms of the transaction have been approved by the Boards of both companies. The transaction is subject to approval of the required capital increase by Evolva’s shareholders and is expected to close in late Q2 or early Q3 2011.

Prof. Erich Schlick, MD, Chairman of Evolva’s Board of Directors: “We believe the combination with Abunda is strongly value-adding for our shareholders. Abunda brings a unique and highly synergistic combination of IP, a number of exciting product candidates and a highly experienced team with a successful track record in the nutrition industry. This transaction is in line with our strategy to maximise our innovative technology platform by discovering, developing and manufacturing high-value active ingredients to enable novel products for the pharmaceutical, consumer healthcare and nutrition markets.”

Neil Goldsmith, Chief Executive Officer of Evolva, said: “High-performance nutritional ingredients are becoming more valuable as both food and pharmaceutical companies seek better ways to deliver health benefits to consumers and patients around the world. We are excited by the commercial potential of the Stevia products we are developing together with Abunda and believe they create significant additional partnering opportunities for Evolva.

We intend to commercialise Stevia following our established business-to-business model and expect to actively enter collaborations with companies regarding manufacturing scale-up and commercialisation. We believe products containing pure, fermentation derived Stevia components should be widely available in the next few years and that these will deliver winning combinations of health, taste and value to consumers around the world.”

Simon Waddington, Ph.D., Chief Executive Officer of Abunda, said: “We are extremely pleased to be joining forces with our long-time partners. Combining the expertise of both companies will significantly accelerate the development of our novel, next-generation nutritional products.”

Stuart Strathdee, Ph.D. Abunda board member and former Tate & Lyle plc Executive Director, said:”Stevia has already captured the imagination of the world’s leading food and beverage companies because amongst other properties it has zero calories, does not trigger the problematic glycaemic response caused by ordinary white table sugar or cereal-based sweeteners such as high fructose corn syrup, and is 200-300 times sweeter than sugar. For food and beverage manufacturers, the availability of pure, fermentation-derived Stevia components and the ability to customise their blending should represent a leap forward in terms of the sweetener’s taste and economic attractiveness.”

Ganesh Kishore, Ph.D. Abunda scientific founder, board member and former President of Nutrition and Consumer Products Division of Monsanto, added: “Evolva is now exceptionally well positioned to tap into food and pharma industry interest in developing a whole new generation of product solutions for addressing the epidemic that is diabetes, obesity, and other maladies associated with metabolic syndrome, integrating dietary solutions with drug therapy.”

Prof. Jutta Heim, Ph.D., Chief Scientific Officer of Evolva, said: “We have collaborated very successfully with Abunda over the last two years in applying Evolva’s technologies to the production of Stevia ingredients by fermentation. Our teams know and work with each other very well, so we anticipate a straightforward and seamless integration with even greater success in the future. Over the next 12 - 18 months, our task on Stevia is to further improve the yield and transfer to the scale-up phase. We will also progress the wider nutrition portfolio together with the people joining us from Abunda.”

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.